🇺🇸 FDA
Patent

US 8088809

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

granted A61PA61P1/04A61P1/16

Quick answer

US patent 8088809 (Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes) held by Jenrin Discovery, LLC expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Jenrin Discovery, LLC
Grant date
Tue Jan 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61P, A61P1/04, A61P1/16, A61P11/00, A61P13/08